These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20930514

  • 1. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ.
    Cancer Biol Ther; 2010 Dec 01; 10(11):1091-7. PubMed ID: 20930514
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R.
    Cancer Invest; 2005 Dec 01; 23(4):303-8. PubMed ID: 16100942
    [Abstract] [Full Text] [Related]

  • 3. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS.
    Cancer; 2008 Oct 01; 113(7):1632-40. PubMed ID: 18720480
    [Abstract] [Full Text] [Related]

  • 4. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct 01; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 5. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    de Gast GC, Batchelor D, Kersten MJ, Vyth-Dreese FA, Sein J, van de Kasteele WF, Nooijen WJ, Nieweg OE, de Waal MA, Boogerd W.
    Br J Cancer; 2003 Jan 27; 88(2):175-80. PubMed ID: 12610499
    [Abstract] [Full Text] [Related]

  • 6. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ.
    Cancer Biol Ther; 2015 Jan 27; 16(5):662-70. PubMed ID: 25806780
    [Abstract] [Full Text] [Related]

  • 7. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
    Guillot B, Khamari A, Cupissol D, Delaunay M, Bedane C, Dreno B, Picot MC, Dereure O.
    Melanoma Res; 2008 Apr 27; 18(2):141-6. PubMed ID: 18337651
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
    Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J.
    Melanoma Res; 2006 Aug 27; 16(4):357-63. PubMed ID: 16845332
    [Abstract] [Full Text] [Related]

  • 11. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
    Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA.
    J Immunother Cancer; 2017 Sep 19; 5(1):74. PubMed ID: 28923120
    [Abstract] [Full Text] [Related]

  • 12. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR.
    J Clin Oncol; 2007 Jun 20; 25(18):2540-5. PubMed ID: 17577032
    [Abstract] [Full Text] [Related]

  • 14. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
    Powell S, Dudek AZ.
    Anticancer Res; 2009 Oct 20; 29(10):4189-93. PubMed ID: 19846971
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D.
    Ann Oncol; 2008 Apr 20; 19(4):801-6. PubMed ID: 18178958
    [Abstract] [Full Text] [Related]

  • 17. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS, Kirkwood JM.
    Cancer; 2003 Jan 01; 97(1):121-7. PubMed ID: 12491513
    [Abstract] [Full Text] [Related]

  • 18. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
    Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C.
    Ann Oncol; 2006 Oct 01; 17(10):1592-7. PubMed ID: 17005632
    [Abstract] [Full Text] [Related]

  • 19. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
    Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, II Smith W, Dutcher P, Gollob J, Longmate J, Johnson D.
    J Cancer Res Clin Oncol; 2002 Apr 01; 128(4):214-8. PubMed ID: 11935312
    [Abstract] [Full Text] [Related]

  • 20. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G.
    BMC Cancer; 2018 May 10; 18(1):552. PubMed ID: 29747595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.